Tirzepatide 12 mg PeptideSciences

Description and price of Tirzepatide 12 mg

Tirzepatide has been developed specifically for use in the treatment of type II diabetes. However, it is also an active cardiovascular protector and has shown high efficacy as a weight loss agent.

Tirzepatide is a synthetic compound derived from gastric inhibitory polypeptide (GIP), which is also known to act as glucagon-like peptide-1 (GLP-1). This combination allows tirzepatide to lower blood glucose levels, increase insulin sensitivity and improve satiety, all of which contribute to weight loss.

Buy Tirzepatide online

Tirzepatide, which consists of 39 amino acids, is a synthetic analogue of gastric inhibitory polypeptide (GIP). It stimulates the secretion of insulin from the pancreas by binding to GIP and GLP-1 receptors. Adiponectin levels increase by 26% with long-term use of tirzepatide. It has been shown to lower insulin levels and improve insulin sensitivity, decrease hunger, leading to better glucose tolerance, lower cardiovascular risk, less fat tissue and weight loss of up to 11kg.

What is the effect of Tirzepatide? 

Tirzepatide works by stimulating the pancreas to release insulin. In people with type II diabetes, this peptide reduces haemoglobin A1c (HbA1c) levels by 2.4% after 6 months of treatment. It also helps people lose up to 11 kg of excess weight, with a dose-dependent effect.

Tirzepatide does not just increase the release of insulin. Importantly, it also significantly improves the function of the beta cells in the pancreas that are responsible for the synthesis and secretion of insulin. The beta cells become more efficient at processing insulin, leading to an increase in its levels in the blood, and the stress on the beta cells themselves is reduced, which may slow the progression of type II diabetes.

Action of Tirzepatide

Tirzepatide is given by subcutaneous injection once a week at a starting dose of 0.5-1 mg. The dose is gradually increased over 4-20 weeks to reach the target dose of 5 mg, 10 mg or 15 mg once weekly. 15 mg once weekly is the maximum dose possible.

Tirzepatide works by activating the receptors for the hormones GIP and GLP-1, which are released from the gut. This reduces appetite and the frequency of eating.

Tirzepatide is more effective than the potent GLP-1 agonists already approved for the treatment of type II diabetes.

Gastric inhibitory polypeptide is naturally synthesised in the small intestine and is also known as glucose-dependent insulinotropic polypeptide. Tirzepatide binds to the GIP receptor, thereby inhibiting the release of gastric acid and stimulating insulin release. Releasing insulin is the main function of the GIP-R receptor and the main reason why insulin levels rise after eating.

Beta cells and neurons in the human brain contain GLP-1R receptors. GLP-1R stimulation has a dual effect: it activates insulin secretion by beta cells and reduces appetite by brain command.

The combination of GIPR and GLP-1R gives tirzepatide a significant advantage over pure GLP-1R agonists. Tirzepatide acts in the same way as GIP, but promotes the formation of cAMP, whereas when it acts on the GLP-1R it recruits β-arrestin. As a result, tirzepatide increases GLP-1R activity compared to endogenous GLP-1 or other synthetic agonists. This means that tirzepatide significantly increases insulin secretion, stops inflammatory processes in adipose tissue and reduces hunger. The combination of these effects makes this peptide very effective in the treatment of type II diabetes.

Tirzepatide also changes the amount of adiponectin by increasing the amount of fat-burning peptides. Elevated levels of adiponectin reduce fat cell differentiation and increase energy expenditure, making mitochondria less efficient. Low levels of this peptide hormone are associated with diseases such as type II diabetes, atherosclerosis and non-alcoholic fatty liver disease. 

Insulin sensitivity increases when adiponectin levels rise. Several mechanisms are thought to be involved in the regulation of insulin sensitivity.

Tirzepatide and the feeling of hunger

In the early stages of tirzepatide treatment, gastric emptying is delayed. Over time, the peptide's effect diminishes due to tachyphylaxis. This effect is very similar to the one observed with the pure GLP-1R agonists. It seems that this effect of tirzepatide is controlled by GLP-1 activity and not by GIP.

It is likely that this effect of the peptide on gastric emptying can be prolonged if tirzepatide is taken at a low dose for a month and then gradually increased.

Using this regimen will also help to reduce the side effects of the drug. The slower emptying of the stomach means that you feel fuller for longer, which helps to decrease food cravings. This feature of tirzepatide, together with its ability to influence the amount of glucose, can help to maintain a proper diet.

Brief summary of Tirzepatide

Tirzepatide is a synthetic peptide that is derived from gastric inhibitory polypeptide (GIP) and at the same time has the functionality of glucagon-like peptide-1 (GLP-1). This combination enables tirzepatide to reduce blood glucose, enhance insulin sensitivity and prevent hunger, thereby accelerating weight loss. Developed to treat type II diabetes, Tirzepatide also provides cardiovascular protection and is a strong weight loss ingredient.

Tags: Tirzepatide 12 mg PeptideSciences, Fat burners